Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on March 6, 2015. The filing reports the entry into a material definitive agreement on March 6, 2015, and references a press release issued on March 12, 2015.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on a specific contractual commitment.
- Contract Value: Anticipated total payment not to exceed approximately $14,941,804.
- Direct Fees: $8,866,490.71.
- Pass-Through Costs: Estimated at $6,075,313.45.
- Payment Terms: Payments to be made on a periodic basis as described in the Project Addendum.
Material Changes
On March 6, 2015, the company entered into a Project Addendum to a Master Services Agreement (originally dated January 8, 2015) with PPD Development, L.P. Prior to this Addendum, neither party had material obligations under the Master Services Agreement. This agreement formalizes PPD's role in providing clinical development services for Galectin's Phase II NASH-CX study.
Outlook, Risks, and Unusual Items
Management Commentary: The agreement enables the execution of the Phase II NASH-CX study. The term of the Addendum commences on the effective date and ends upon completion of services.
Termination and Contingencies: The agreement is terminable by either party on 30 days' notice. In the event of early termination, Galectin is obligated to pay all direct fees and pass-through costs for services performed through the termination date.
Confidentiality: Portions of the Project Addendum exhibit have been omitted from the public filing due to a request for confidential treatment.
Investor Verification Checklist
- Verify the company's current cash position to ensure it can fund the anticipated $14.9 million in contract payments.
- Review the full text of the Project Addendum (Exhibit 10.1) filed separately with the SEC to understand the specific milestones triggering payments.
- Monitor the progress of the Phase II NASH-CX study, as this contract is contingent on the study's execution.
- Check for any subsequent filings regarding the confidential portions of the agreement.